Sensory Medical

Oct 21, 2014

Tweet October 21, 2014 by Alexander Soule Sensory Medical announces a $1.4 million tranche in a funding round for its Relaxis device to relieve symptoms of restless legs syndrome. Sensory Medical shook a leg on a 2nd tranche of funding since receiving FDA clearance last spring for its device to relieve symptoms of restless legs syndrome, reporting $1.4 million in fresh funding on the heels of a $1 million tranche in June. Restless leg syndrome is a neurological disorder that causes sensations giving people the urge to move and reposition their legs to relieve discomfort, disrupting their sleep. Scientists have yet to pin down the cause of RLS, but some suspect it is genetic in origin. Sign up to get our free newsletters delivered straight to your inbox In addition to recommending decreased intake of caffeine, alcohol and other substances, doctors often prescribe medication to alleviate RLS, with mixed results. San Clemente, Calif.-based Sensory Medical announced FDA approval in May for the Relaxis system, a flat pad that delivers vibrations to the leg as an alternative to medication. Similar entries NxStage touts study results showing improved sleep, less restless legs "Our company was founded solely to find new alternatives for treating RLS," co-founder & CEO Dr. Fred Burbank said at the time. "We are pleased to be the 1st and only company to have a non-pharmacological approach, clinically proven and FDA-cleared, to improve sleep by addressing symptoms. "